Summit Therapeutics (SMMT) Net Income towards Common Stockholders: 2016-2024
Historic Net Income towards Common Stockholders for Summit Therapeutics (SMMT) over the last 3 years, with Dec 2024 value amounting to -$65.6 million.
- Summit Therapeutics' Net Income towards Common Stockholders fell 81.23% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$183.2 million, marking a year-over-year decrease of 94.97%. This contributed to the annual value of -$234.7 million for FY2024, which is 61.84% up from last year.
- As of Q4 2024, Summit Therapeutics' Net Income towards Common Stockholders stood at -$65.6 million, which was down 7.88% from -$60.8 million recorded in Q3 2024.
- Summit Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$7.4 million during Q1 2020, with a 5-year trough of -$65.6 million in Q4 2024.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was -$28.4 million (2023), whereas its average is -$36.7 million.
- Data for Summit Therapeutics' Net Income towards Common Stockholders shows a maximum YoY slumped of 196.86% (in 2024) over the last 5 years.
- Summit Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$7.4 million in 2020, then reached -$20.3 million in 2022, then plummeted by 78.38% to -$36.2 million in 2023, then tumbled by 81.23% to -$65.6 million in 2024.
- Its last three reported values are -$65.6 million in Q4 2024, -$60.8 million for Q3 2024, and -$36.2 million during Q4 2023.